DB1, a capsid developed by Shape Therapeutics, to deliver therapies to the brain, including VectorY’s developmental ...

Both BMS and Novo Nordisk have, in recent months, announced steep layoffs as they strive to cut back on costs.

The star of the acquisition, which includes a contingent value right of $6 per share, is pegozafermin, an FGF21 analog in ...

Supporting Lexicon Pharmaceuticals’ decision to advance the non-opioid analgesic pilavapadin into late-stage ...

In this episode of Denatured, BioSpace’s head of insights Lori Ellis and Colin Zick, partner at Foley Hoag LLP, spend time ...

This year, Novo Nordisk and Merck announced significant layoffs, with Novo planning to axe about 9,000 employees and Merck projecting it could let go of roughly 6,000. Meanwhile, Bayer, Bristol Myers ...

Brepocitinib remains “ahead of competition” in the dermatomyositis space, according to analysts at Leerink, who projected that the drug candidate could hit $2 billion in sales in 2032.

An IQVIA report published earlier this year found that 43% of anti-obesity assets currently in development are orally administered. By 2030, Goldman Sachs predicts this will translate to the pills’ ...

A complex state vs. federal regulatory scheme allows drug compounders to advertise drugs without disclosing risks like a ...

In letters to Eli Lilly and Novo Nordisk, the FDA accused the companies of downplaying the risks of their GLP-1 weight loss ...

OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster ...

Moving forward, Innate will focus on the clinical development of its antibody-drug conjugate IPH4502, the lymphoma candidate ...